Related Experiment Video
Updated: Sep 29, 2026

Ultrasound-Guided Acupotomy Release With Biomechanical Assessment For Trapezius Myofascial Pain Syndrome
Published on: May 29, 2026
Botulinum toxin therapy for myofascial pain disorders
1orthoREHAB Plus, P.C., 575 Professional Drive, Suite 250, Lawrenceville, GA 30045, USA. orthorehab@earthlink.net
Abstract:
Myofascial pain disorder can originate from various muscles in the body. Numerous therapeutic approaches have been used to treat myofascial pain syndrome with varying success. Botulinum toxin neurolysis may become an important treatment regimen because it sustains relaxation of muscles. There is a growing body of clinical evidence for the efficacy of botulinum toxin in the treatment of painful myofascial conditions. The conditions that have been investigated include chronic low back pain, chronic cervical-associated headache, myofascial pain, myofascial pain syndrome and pain from chronic muscle spasm, and refractory myofascial pain. One of these studies was an open-label, exploratory pilot study into the cervicothoracic and lumbosacral regions using a novel injection technique.
Related Concept Videos
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
Skeletal Muscle Relaxants: Therapeutic Uses
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Classification of Skeletal Muscle Relaxants
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Botulism
Peripherally and Centrally Acting Muscle Relaxants: A Comparison
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic drugs,...

